Related Experiment Video
Updated: Sep 2, 2025
12:55
Generation of CAR T Cells for Adoptive Therapy in the Context of Glioblastoma Standard of Care
Published on: February 16, 2015
21.5K
Ketogenic Metabolic Therapy for Glioma
Kris A Smith1, Benjamin K Hendricks1, Joseph D DiDomenico1
1Neurosurgery, Barrow Neurological Institute, Phoenix, USA.
Cureus
|August 4, 2022
Summary
Ketogenic metabolic therapy, involving diet and fasting, showed promising survival benefits for glioma patients. This approach may enhance standard cancer treatments, warranting further investigation in clinical trials.
Area of Science:
- Neuro-oncology
- Metabolic Therapies
- Dietary Interventions
Background:
- Gliomas are aggressive brain tumors with limited treatment options.
- Standard treatments include surgery, radiation, and chemotherapy.
- Novel therapeutic strategies are needed to improve patient outcomes.
Purpose of the Study:
- To describe a retrospective case series of glioma patients treated with ketogenic metabolic therapy (KMT).
- To evaluate the feasibility and potential efficacy of KMT in this patient population.
Main Methods:
- Retrospective chart review of patients with glioma who adhered to KMT (diet and intermittent fasting) for at least four months.
- Analysis of patient demographics, tumor characteristics (WHO grade, IDH1, MGMT status), and treatment duration.
- Assessment of treatment response using Response Assessment in Neuro-oncology (RANO) criteria.
Main Results:
- Sixteen patients with various glioma grades (II, III, and IV) received KMT.
- Mean duration of KMT was 20.6 months.
- Complete response was observed in 8 patients, partial response in 8 patients, with a mean progression-free survival of 20.0 months.
Conclusions:
- KMT may offer a survival advantage for glioma patients when combined with standard care.
- Strict adherence to KMT appears crucial for potential benefits.
- Prospective studies are needed to validate these findings and explore KMT further.
